Leukemia

TABLE 4

FROM:

Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells

R Suzuki, J Suzumiya, S Nakamura, S Aoki, A Notoya, S Ozaki, H Gondo, N Hino, H Mori, H Sugimori, K Kawa and K Oshimi for the NK-cell Tumor Study Group

BACK TO ARTICLE

Table 4. Therapeutic response and clinical course of aggressive NK-cell leukemia cases

Case no. Chemotherapy Response Outcome Survival (months)
1CY and ETPNRDOD13
2AML regimen (BHAC+DNR+VCR+PSL), CHOPNRDOD1
3THP-COPCRRelapsed and DOD16
4CHOPNRDOD1
5CHOPNR  
 Allo-BMT (remission failure)CRRelapsed and DOD6
6COPNRDOD2
7ADR+VCR+PSLNRDOD1
8COP+BLMNRDOD1
9COPNRDOD2
10DNR+CY+VCR+L-Asp+PSLPRRegrown and DOD5
11CAMBO-VIPNRDOD16
12CHOP+BLMNRDOD1
13PSLUnevaluableEarly death1 day
14THP-COPNRDOD5
15PSL+interferon alphaPRRegrown and DOD6
16MIT+ETPPRRegrown and DOD9
17PSLNRDOD19 days
18VCRUnevaluableEarly death7 days
19CHOPCRDied of GVHD+infection39
 Allo-BMT (first CR) No evidence of relapse 
20No therapyUnevaluableDOD1
21CHOP, ESHAPNRDOD1
22Cyclo-BEAPCRRelapsed and DOD22
 Auto-PBSCT (first CR)   

 CY, cyclophosphamide; ETP, etoposide; BHAC, behenoyl cytosine arabinoside; DNR, daunorubicin; VCR, vincristine; PSL, predonisone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; THP, tetrahydropyranyl adriamycin (pirarubicin); COP, cyclophosphamide, vincristine and prednisone; BMT, bone marrow transplantation; ADR, doxorubicin (adriamycin); BLM, bleomycin; l-Asp, l-asparaginase; CAMBO-VIP, cyclophosphamide, doxorubicin, methotrexate, bleomycin, vincristine, etoposide, ifosphamide, and predonisone; MIT, mitoxantrone; ESHAP, etoposide, methylprednisolone, cytarabine and cisplatin; DOD, died of disease.

BACK TO ARTICLE